Intercos (ICOS) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
18 Aug, 2026Executive summary
Achieved record Q2 net sales of €285.1 million, up 4.9% at constant FX and 4.0% at reported FX, nearly matching the prior year’s first half and offsetting a weak Q1.
Q2 Adjusted EBITDA reached an all-time high of €47.5 million (16.7% margin), up 5% year-over-year; H1 Adjusted EBITDA was €72.6 million (14.2% margin), down 2.6% year-over-year.
Net income for H1 rose 33% to €27.6 million, driven by strong Q2 EBITDA, lower financial costs, and a reduced tax rate.
Net debt decreased by €11.8 million to €122.7 million, with leverage ratio reduced to 0.80x, despite €16.9 million in share buybacks and €18.5 million in dividends.
Launched a new Sustainability Plan with 24 ESG goals through 2035, reinforcing commitment to sustainable practices.
Financial highlights
H1 net sales were €512.5 million, down 0.5% at constant FX and 2.4% at reported FX year-over-year; Q2 sales up 4.9% at constant FX.
Value Added Sales (VAS) for H1 were €404.6 million, nearly flat year-over-year, but up low-single-digit at constant rates.
Gross margin for H1 improved by 36 basis points to 21.7%, aided by operational efficiencies and a lower packaging rate.
H1 operating cash flow reached €26.2 million, up €18.6 million year-over-year, with a 75% conversion rate after CapEx.
EBIT margin for H1 was 8.1%, down 24bps year-over-year.
Outlook and guidance
Full-year 2026 guidance confirmed, with expectations for global beauty market growth of 4%-5% and strong acceleration in H2 sales, especially in Makeup and Hair & Body.
Robust order book, up mid-teens year-over-year, provides visibility for continued top-line growth in H2.
Consensus for full-year EBITDA of €164 million and stable margins is considered accurate.
Effective tax rate expected to normalize at 30%-31%; finance costs projected at €12-12.5 million.
Latest events from Intercos
- Q1 2026 sales fell 6.3% at constant FX, but strong orders and innovation support a positive outlook.ICOS
Q1 2026 - Record profitability and margin expansion achieved despite FX headwinds; growth expected in 2026.ICOS
Q4 2025 - Adjusted EBITDA up 12.3% in 9M25, with Make-up driving growth and margin improvement.ICOS
Q3 2025 - Strong Make-up growth drove sales and margin gains, despite net profit pressure from FX.ICOS
Q2 2025 - Record Q2 EBITDA and sales drive strong H1 and positive outlook for H2 2024.ICOS
Q2 2024 - Q3 sales and EBITDA up over 12%, driven by Asia and EMEA, with margin pressure ongoing.ICOS
Q3 2024 - Q1 2025 sales up 13.4% and EBITDA up 40.6%, driven by Make-up and multinational demand.ICOS
Q1 2025 - 2024 sales rose 7.8% to €1.06B, EBITDA up 4.3%, with strong Asia growth and 2025 guidance at 5–7%.ICOS
Q4 2024